CJC-1295 / Ipamorelin Blend
10mg/vial (5mg+5mg)
Synergistic GHRH + GHRP blend for pulsatile GH axis research.
Price per vial
$109.99
10mg/vial (5mg+5mg)
Concentration
10mg/vial (5mg+5mg)
Warehouse
US Domestic
Product Description
A combination of CJC-1295 without DAC (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act through distinct but complementary receptor pathways to model pulsatile GH release in research.
Research Overview
CJC-1295 (no DAC) amplifies GHRH receptor signaling at the somatotrope, while Ipamorelin activates ghrelin receptors (GHS-R1a) to stimulate GH secretion with high selectivity—minimal cortisol or prolactin interference compared to earlier GHRPs. The combination allows researchers to study the two main GH secretagogue axes simultaneously in a single preparation. For research use only.
Research Applications
Certificate of Analysis (Janoshik)
Research Use Only
This product is intended solely for laboratory research and analytical purposes. Not for human consumption or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.